Show
Sort by
-
- Journal Article
- A1
- open access
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial
-
Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines
-
The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile
-
Three-year follow-up of rituximab in rheumatoid arthritis: results from the Belgian MIRA (MabThera in Rheumatoid Arthritis) registry
-
- Journal Article
- A1
- open access
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy
-
Indications for a genetic association of a VCP polymorphism with the pathogenesis of sporadic Paget's disease of bone, but not for TNFSF11 (RANKL) and IL-6 polymorphisms
-
A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort
-
Hand radiological damage in systemic sclerosis: comparison with a control group and clinical and functional correlations
-
A nationwide survey on patient's versus physician's evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration: the Be-Raise study
-
A twelve-week exploratory phase II trial of GLPG0259 versus placebo in patients with active rheumatoid arthritis and inadequate response to methotrexate